anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Study participants will include 280 children ages 2 months to 8 years old, with a Height for Age Z score (HAZ) less than median for the Parque Universitario community, living in Brazilian favela. Subjects will be enrolled into this prospective, randomized, placebo controlled study of the Long-term Impact and Intervention for Diarrhea in Brazil. Children meeting the inclusion criteria will be prospectively, randomized to four arms: (1) placebo: placebo (2) Vitamin A: Zinc Placebo (3) Vitamin A Placebo:Zinc (4) Vitamin A:Zinc. Intervention will last for one year with two additional years of follow up. A nested study involving all patients will take place at week four. At week four there will be a second randomization to either oral glutamine or glycine (placebo) for an additional ten days. The primary endpoint of the nested study will be the L:M ratio at 6 weeks. The master randomization list will be broken, only by combined approval of the Principal Investigators, at the end of the study or in the unexpected event of a child needing removal from the study (for that case only). All randomized subjects will be visited in their home two times per week for assessment of intercurrent diarrhea. At 1, 4, 8, 12, 24 and 36 months patients will have a nutritional status/anthropometry and diarrheal illness rate assessment. At 0, 1, 1.5, and 4 months all randomized subjects will have a Lactulose:Mannose Ratio (L:M) performed. A blood Zinc and Vitamin A level will be drawn at 0 and 4 months. Also a stool microbiology, lactoferrin and protein loss assessment will be completed at 1 month. All randomized subjects who complete the protocol should have assessments as outlined above at 36 weeks. The primary effect of interest is the difference in mean HAZ changes between children receiving Zinc plus Vitamin A compared to children receiving no Vitamin A or Zinc, averaging the difference in children receiving glutamine and children not receiving glutamine.
FIELD: medicine. SUBSTANCE: method involves applying hyperbaric therapy at pressure chamber at 1.03-1.1 ata pressure on the background of antioxidant administration for increasing mytochondrial oxidation combined with cyclosporin A administration at doses lower than therapeutic ones. Treatment efficiency is controlled with immunity status dynamic data. Immunity status suppression is detected after its activation and then cyclosporin A dose is gradually lowered to cancel it completely. EFFECT: enhanced effectiveness of treatment. 2 dwg
INTRODUCTION: Premenstrual symptoms encompass a range of physical, emotional, and behavioral changes that cyclically occur before menstruation. Childhood abuse has been associated with subsequent mental health challenges, yet its relationship with exacerbating premenstrual symptoms remains an understudied area. Furthermore, suicidal ideation often emerges from traumatic backgrounds such as child abuse, creating another layer of complexity. Given the rising suicide rates in Lebanon, and the concurrent increase in reported child abuse cases, this research focuses on the role of suicidal ideation as a mediator between child abuse and premenstrual syndrome.
METHODS: This cross-sectional study involved 915 female university students in Lebanon. Participants completed an online questionnaire encompassing demographic details, health lifestyle, the Premenstrual Symptoms Screening Tool (PSST), Columbia-Suicide Severity Rating Scale (C-SSRS), and Child Abuse Self Report Scale (CASRS-12). The mediation analysis was conducted using PROCESS MACRO v3.4 model 4; three pathways derived from this analysis: pathway A from the independent variable to the mediator, pathway B from the mediator to the dependent variable, Pathway C indicating the direct effect from the independent to the dependent variable.
RESULTS: The results of the mediation analysis showed that suicidal ideation mediated the association between all types of child abuse and the presence of PMS. Higher psychological (Beta = 0.21; p < 0.001), neglect (Beta = 0.02; p = 0.017), physical (Beta = 0.19; p < 0.001) and sexual (Beta = 0.20, p < 0.001) child abuse were significantly associated with higher suicidal ideation, which was significantly associated with the presence of PMS (Beta = 0.38, p = 0.001; Beta = 0.57, p < 0.001; Beta = 0.45, p < 0.001; and Beta = 0.50, p < 0.001) respectively. Finally, higher psychological (Beta = 0.17, p < 0.001), physical (Beta = 0.11, p = 0.024), but not sexual (Beta = 0.07, p = 0.198) child abuse was directly and significantly associated with the presence of PMS, whereas higher neglect (Beta = -0.06, p = 0.007) was significantly associated lower odds of having PMS.
CONCLUSION: This study highlights the mediating role of suicidal ideation in the complex association between different types of childhood abuse and premenstrual symptoms. The findings emphasize the need for trauma-informed care and tailored interventions to address the diverse impact of these factors. Recognizing the intricate relationships between child abuse, suicidal ideation, and PMS can aid healthcare providers in comprehensively addressing young women's mental and reproductive well-being. Trauma-informed care, tailored interventions and awareness of potential connections between childhood maltreatment are essential in managing these complex challenges.
In malaria-endemic areas of Sub-Saharan Africa, overlap of clinical symptoms between malarial and non-malarial febrile illnesses can lead to empiric use of antibiotics among children. Our study aimed to illustrate the potential impact of decreasing malaria prevalence from malaria control efforts on antibiotic use. We constructed a probabilistic decision tree model representing antibiotic prescription in febrile children < 5 years. This model was used to predict change in absolute antibiotic use compared to baseline under levels of decreasing malaria prevalence. Model parameters were based on data from a hospital study in Ghana and validated via literature review. The baseline prevalence of malaria diagnoses was 52% among all hospitalized children. For our main results, we reported outcomes for a scenario representing a 50% decrease in malaria prevalence. Compared to baseline, absolute antibiotic prescription decreased from a baseline of 639 doses (95% CI 574-694) to 575 (95% CI 502-638). This reflected a 10% (95% CI 7%-13%) decrease in absolute antibiotic use. Our findings demonstrate that effective malaria control can reduce pediatric antibiotic use. However, until substantial progress is made in developing accurate diagnostics for non-malarial febrile illnesses, further reductions in antibiotic use will remain a challenge.
The invention relates to a trigold nourishing paste for nourishing and beautifying, and three Chinese medicines which are turnip, trichosanthes and peach kernel are added with porcine pancreas, and then the mixture is added with proper amount of yellow rice wine according to the dose, put into a stone mortar and mashed into muddy paste. The paste is used for nourishing and beautifying females with sallow and withered complexion caused by malnutrition. In winter, the paste can be used as hand-care paste and smeared to protect hands with the efficacies of anti-freezing and anti-cracking. High qualified porcine pancreas and the three Chinese medicines (washed clean without impurity) are selected. Each packet of the medicine contains five porcine pancreas, 150g of peach kernel, 250g of trichosanthes, 100g of turnip and proper amount of yellow rice wine. The paste is suitable for females with sallow and withered complexion and chocolate spot. The paste is smeared on the face every night before sleep and is washed by warm water the next day (if the paste is used in daytime, back lying for half an hour is needed and exposing to the weather is forbidden). The pungent and hot should be avoided.
The research is a randomized controlled, quasi-experimental study. The population of the study consisted of 130 first-year students enrolled at Gülhane Faculty of Nursing, University of Health Sciences. In the study, a mobile augmented reality application was used for the training of students in the intervention group regarding pressure injury prevention. The training of the control group students continued with traditional education methods. The data collection process of the study was carried out in two stages: preparation and implementation. Prior to the commencement of the study, ethical committee approval and institutional permissions were obtained. In the analysis of the data, descriptive statistical methods such as number, percentage, min-max values, median, mean, and standard deviation were used, along with independent t-test, dependent t-test, and Chi-square analysis.
OBJECTIVE: This study aimed to analyze the prevalence, risk factors, and clinical implications of hemolyzed laboratory samples in the pediatric emergency department (ED), a subject on which existing data remains scarce.
METHODS: We conducted a multi-site observational cohort analysis of pediatric ED encounters in Metro Detroit, Michigan, United States. The study included participants below 18 years of age who had undergone peripheral intravenous catheter (PIVC) placement and laboratory testing. The primary outcome was the presence of hemolysis, and secondary outcomes included identifying risk factors for hemolysis and assessing the impact of hemolysis on PIVC failure.
RESULTS: Between January 2021 and May 2022, 10,462 ED encounters met inclusion criteria, of which 14.0% showed laboratory evidence of hemolysis. The highest proportion of hemolysis occurred in the infant (age 0-1) population (20.1%). Multivariable regression analysis indicated higher odds of hemolysis for PIVCs placed in the hand/wrist in the toddler (age 2-5) and child (age 6-11) subgroups. PIVCs placed in the hand/wrist also demonstrated higher odds of failure in infants.
CONCLUSIONS: Hemolysis in the pediatric ED population is a frequent complication that occurs at similar rates as in adults. PIVCs placed in the hand/wrist were associated with higher odds of hemolysis compared to those placed in the antecubital fossa. Clinicians should consider alternative locations for PIVC placement if clinically appropriate. Further research is needed to better understand the clinical implications of pediatric hemolysis.
The present invention relates to a method for manufacturing a dyeing composition and a dyeing composition manufactured by the same. The method for manufacturing a dyeing composition comprises: a base material preparation step of preparing a base material comprising cinnamon, alum, green tea leaves, and silkworms; an extraction step of inserting the base material with purified water in an extraction container and then heating and extracting the same; an extract liquid acquisition step of acquiring extract liquid from which the cinnamon, the green tea leaves, and the silkworms have been sieved and removed after the extraction step; an insertion and agitation step of inserting a functional material including dimethylsulfone, glycerin, sodium benzoate, carboxymethylcellulose, and an egg yolk extract into the extract liquid acquired by the extract liquid acquisition step and agitating the same; and a henna powder insertion step of inserting henna powder into an agitated product having been processed by the insertion and agitation step. The dyeing composition comprising henna is easy to use and thus enables an unskilled user to dye his or her hair by him or herself. Since a user can obtain enough dyeing effect with only one-time treatment, the user does not need to perform repeated treatments. Lasting power of dyeing of the dyeing composition is excellent. In addition, the dyeing composition prevents hair loss by reinforcing hair roots, provides an anti-inflammatory effect, and can prevent odor from being generated by the generation of dandruff and sebum.
Double lumen tube (DLT) is an enotracheal tube that facilitates one lung ventilation. The efficiency of the DLT depends on its exact position in the airways, as verified by fiber-optic bronchoscopy (FOB) after intubation, and re-verified after positioning the patient on the lateral position. The VivaSight TM DL is a single use left DLT with a camera embedded in the tube's right side port. The view from the camera appears continuously on a monitor. This study was designed to compare the VivaSightTM DL to the standard DLT. The primary end point is the time required for intubation with visual confirmation of DLT position.
Gene therapy offers a promising avenue for treating ischemic diseases, yet its clinical efficacy is hindered by the limitations of single gene therapy and the high oxidative stress microenvironment characteristic of such conditions. Lipid-polymer hybrid vectors represent a novel approach to enhance the effectiveness of gene therapy by harnessing the combined advantages of lipids and polymers. In this study, we engineered lipid-polymer hybrid nanocarriers with tailored structural modifications to create a versatile membrane fusion lipid-nuclear targeted polymer nanodelivery system (FLNPs) optimized for gene delivery. Our results demonstrate that FLNPs facilitate efficient cellular uptake and gene transfection via membrane fusion, lysosome avoidance, and nuclear targeting mechanisms. Upon encapsulating Hepatocyte Growth Factor plasmid (pHGF) and Catalase plasmid (pCAT), HGF/CAT-FLNPs were prepared, which significantly enhanced the resistance of C2C12 cells to H2O2-induced injury in vitro. In vivo studies further revealed that HGF/CAT-FLNPs effectively alleviated hindlimb ischemia-induced gangrene, restored motor function, and promoted blood perfusion recovery in mice. Metabolomics analysis indicated that FLNPs didn't induce metabolic disturbances during gene transfection. In conclusion, FLNPs represent a versatile platform for multi-dimensional assisted gene delivery, significantly improving the efficiency of gene delivery and holding promise for effective synergistic treatment of lower limb ischemia using pHGF and pCAT.
The investigators propose a novel treatment strategy that involves Abl inhibition to alter Abeta40/42, total Tau and p-Tau231/181 in subjects with mild to moderate dementia due to AD. The investigators pre-clinical studies show that Nilotinib inhibits brain Abl, decreases Abeta and p-Tau, modulates brain and peripheral immune profiles and reverses cognitive decline in AD models. Taken together, these data support the hypothesis that Nilotinib is a viable therapeutic candidate - via Abl inhibition - in subjects with AD. Based on strong pre-clinical evidence about the effects of Nilotinib on neurodegenerative pathologies, including autophagic clearance of neurotoxic proteins, immunity and behavior, the investigators conducted an open label pilot clinical trial in advanced (stage 3-5) PD with dementia (PDD) and Lewy Body Dementia (LBD) patients. Participants (N=12) were randomized 1:1 to once daily oral dose of 150mg and 300mg Nilotinib for 6 months. The investigators showed that Nilotinib penetrates the blood brain barrier (BBB), in agreement with pre-clinical data. Several studies show that Abeta42 is decreased and CSF total Tau and p-Tau are increased in PD and LBD. Investigators data show that Nilotinib reverses loss of CSF Abeta40/42 and significantly reduces (N=5, P\<0.05) CSF total Tau and p-Tau between baseline and 6 months treatment. These biomarker changes are consistent with cognitive improvement (3.5-3.85 points) using Mini-Mental Status Exam (MMSE) and the Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA-Cog) between baseline and 6 months. These data are very compelling to evaluate the effects of Nilotinib in a phase II, randomized, double-blind, placebo-controlled trial in patients with mild to moderate AD.
Chronic kidney disease (CKD) poses a substantial global health burden. It is classified according to estimated glomerular filtration rate (eGFR) (G1-G5) and albuminuria (A1-A3). In recent years the clinicians' therapeutic options for slowing CKD progression and mitigating cardiovascular disease has been significantly expanded:For CKD with albuminuria, concomitant cardiovascular disease or diabetes mellitus, a target blood pressure <130/80mmHg should be aspired. Apart from the geriatric population and those with a life expectancy below one year a blood pressure <140/90mmHg should be targeted. Renin-angiotensin-system inhibitors (RASi) and sodium-glucose-cotransporter 2 inhibitors (SGLT2i) are the basis of CKD therapy. SGLT2i can be prescribed in most cases of CKD with an eGFR >20ml/min/1.73m2 apart from a few exceptions. Once started, patients should stay on SGLT2i until dialysis. Finerenon is a novel option for diabetic nephropathy with an ACR >30mg/g [3mg/mmol] and an eGFR >25ml/min/1.73m2. Finerenon slows CKD progression and reduces cardiovascular events.
This is a prospective, randomized, double blind, placebo controlled, multi-center study in diabetic subjects with the anemia of chronic kidney disease. Subjects will be randomly assigned in a 1:1 ratio to receive either Epoetin alfa (PROCRIT®) or matching placebo for sixteen weeks. Epoetin alfa (PROCRIT®) is indicated for the treatment of anemia associated with chronic renal failure (pre-dialysis), non-myeloid malignancies receiving chemotherapy, in HIV-infected subjects receiving zidovudine therapy, and in anemic subjects undergoing elective non-cardiac, non-vascular surgery to reduce the need for allogenic blood transfusion during high-volume blood loss procedures. This study is being undertaken to assess, under well-controlled conditions, the effect of weekly Epoetin alfa (PROCRIT®) treatment on hemoglobin response in diabetic subjects with the anemia of chronic kidney disease. The study hypothesis is that weekly PROCRIT treatment will be effective in achieving a hemoglobin response than placebo, where hemoglobin response is defined by at least a 1 gram/deciliter increase from baseline by Week 17. The subjects are administered study drug (PROCRIT® or matching placebo) once weekly by subcutaneous injection by a health care professional for 16 weeks. The initial dose of study drug is either PROCRIT® 10,000 U (1.0 mL) or matching placebo. The maximum dose administered is 20,000 U (2.0 mL).
This study, a two group randomised controled trial, investigates whether an intervention for parents would persuade them to enforce smoking bans inside the home and in other locations. A total of 130 parents with children aged 12 months or younger will be recruited. Each group (n=65) will complete a baseline and follow up questionnaire. Urine samples from the infants will be collected to measure the amount of cotinine, a metabolite of nicotine. The parent-report and infant's urinary cotinine measures will be obtained at baseline and at a 3-month follow up. In the intervention group, parents will be given three counselling sessions. For mothers, one being face to face and two telephone counselling and for fathers we will conduct three telephone counselling. The control group receives no intervention. Both groups will also complete a Fagerstrom test for nicotine dependence.
A new ocular contact lens has been designed to increase the amount of light reaching the retina. The contact lens edge is chamfered to redirect and increase the light reaching the retina. A light source encircles and contacts the straight or curved chamfered edge. Additionally, a reflective cylinder and its top wall encircle the lens to block any loss of light. This distal edge of the contact lens may be rounded to increase the angle of retina visible. A new ocular imaging camera has a low-light camera subassembly with server, a photosensor next to low-light camera, a short cylindrical housing, a space between the camera subassembly and the housing, an internal program in server to detect good or poor image quality and an alarm for poor image quality, wherein an operator recaptures the image. A system has a highly efficient method to screen and diagnose a large number of patients using the new ocular contact lens and ocular imaging camera. The system receives and processes the photographs. The photographs are transmitted to eye care specialists' smart phone, tablet or virtual reality device for evaluation. As specified, the eye care specialist separates normal from abnormal, diagnoses the abnormality, and may even provide detailed information, such as the grade of the abnormality. The server receives this information and automatically generates the suitable report for the healthcare professional. The server also processes payment to the eye care specialist.
Participants in this arm will be administrated with HEV vaccine. The immunization schedule is 0,1,6 months.
Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm I.
The procedure of this protocol was performed by a placebo coil, lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT). No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
PCT No. PCT/FR97/01633 Sec. 371 Date Mar. 16, 1999 Sec. 102(e) Date Mar. 16, 1999 PCT Filed Sep. 17, 1997 PCT Pub. No. WO98/11881 PCT Pub. Date Mar. 26, 1998A pharmaceutical composition, comprising a lipophilic phase and, as active principle, at least one compound selected from an optically active isomer or a racemate of amisulpride; an optically active isomer or a racemate of a pharmaceutically acceptable acid addition salt of amisulpride; an optically active isomer or a racemate of a quaternary ammonium salt of amisulpride; and an optically active isomer or a racemate of an oxide of amisulpride.
Patients with primary immunodeficiency will switch to Shu Yang IVIG and optimize the posology to IgG 300 to 600 mg every 21 or 28 days in a run-in period of 2 to 6 administrations, aiming at keeping the IgG trough levels above 5 g/L. In the one-year test period, the patients will receive the test IVIG at the same dose/intervals of the optimization. However, the IgG trough levels will be monitored every visit, and new adjustments/dose optimization will be performed whenever needed to keep the IgG trough levels above 5g/L.
PURPOSE:An antirheumatic agent containing a dithiol derivative. CONSTITUTION:An antirheumatic agent, containing a compound expressed by the formula (R<1> and R<2> are 1-5C alkyl) and an adrenocortical steroidal agent together, and administrable orally or parenterally to mammals including humans. The dosage form thereof is powder, granule, tablet, embrocation, sugar-coated tablet, pill, capsule, suppository, suspension, solution, emulsion, ampule, injection, aerosol and inhalant, etc. The compound expressed by the formula which is an active constituent is contained in an amount of 0.01-100wt% in the composition. The dose thereof is 0.1-500mg/kg/day, preferably 1-200mg/kg/day for oral administration and 0.01-250mg/kg/day, preferably 0.1-100mg/kg/day for parenteral use. In the case of a high dose, administration in several portions is preferred.
A nutrition plan includes a plurality of nutrition skills. Each nutrition skill is divided into several nutrition subskills. The nutrition skill is presented to the user. After an elapsed period of time, the user is asked a nutrition related question. The user responds, and a nutrition progress report is received. The nutrition progress report is checked against a nutrition goal. If user meets the goal, a second nutrition skill is presented. If the user does not meet the goal, then the first nutrition skill is repeated until the user meets the goal.